Denmark · Delayed Price · Currency is DKK Novozymes Statistics
Total Valuation
Novozymes has a market cap or net worth of DKK 202.07 billion. The enterprise value is 222.70 billion.
| Market Cap | 202.07B |
| Enterprise Value | 222.70B |
Important Dates
The next confirmed earnings date is Thursday, November 5, 2026.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | Aug 25, 2026 |
Share Statistics
Novozymes has 465.91 million shares outstanding. The number of shares has increased by 64.53% in one year.
| Current Share Class | 412.17M |
| Shares Outstanding | 465.91M |
| Shares Change (YoY) | +64.53% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 28.00% |
| Float | 346.59M |
Valuation Ratios
The trailing PE ratio is 42.28 and the forward PE ratio is 25.13. Novozymes's PEG ratio is 3.01.
| PE Ratio | 42.28 |
| Forward PE | 25.13 |
| PS Ratio | 6.21 |
| PB Ratio | 2.39 |
| P/TBV Ratio | 753.28 |
| P/FCF Ratio | 31.41 |
| P/OCF Ratio | 20.23 |
| PEG Ratio | 3.01 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.34, with an EV/FCF ratio of 34.66.
| EV / Earnings | 46.59 |
| EV / Sales | 6.85 |
| EV / EBITDA | 18.34 |
| EV / EBIT | 29.55 |
| EV / FCF | 34.66 |
Financial Position
The company has a current ratio of 1.74, with a Debt / Equity ratio of 0.28.
| Current Ratio | 1.74 |
| Quick Ratio | 1.04 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 1.91 |
| Debt / FCF | 3.61 |
| Interest Coverage | 13.94 |
Financial Efficiency
Return on equity (ROE) is 5.77% and return on invested capital (ROIC) is 5.68%.
| Return on Equity (ROE) | 5.77% |
| Return on Assets (ROA) | 3.79% |
| Return on Invested Capital (ROIC) | 5.68% |
| Return on Capital Employed (ROCE) | 6.49% |
| Weighted Average Cost of Capital (WACC) | 7.05% |
| Revenue Per Employee | 2.89M |
| Profits Per Employee | 425,486 |
| Employee Count | 11,263 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 2.29 |
Taxes
In the past 12 months, Novozymes has paid 1.28 billion in taxes.
| Income Tax | 1.28B |
| Effective Tax Rate | 21.32% |
Stock Price Statistics
The stock price has increased by +5.88% in the last 52 weeks. The beta is 0.62, so Novozymes's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | +5.88% |
| 50-Day Moving Average | 432.09 |
| 200-Day Moving Average | 401.13 |
| Relative Strength Index (RSI) | 53.31 |
| Average Volume (20 Days) | 623,753 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novozymes had revenue of DKK 32.13 billion and earned 4.72 billion in profits. Earnings per share was 10.12.
| Revenue | 32.13B |
| Gross Profit | 18.11B |
| Operating Income | 7.48B |
| Pretax Income | 6.00B |
| Net Income | 4.72B |
| EBITDA | 12.03B |
| EBIT | 7.48B |
| Earnings Per Share (EPS) | 10.12 |
Balance Sheet
The company has 2.31 billion in cash and 22.94 billion in debt, with a net cash position of -20.63 billion or -44.28 per share.
| Cash & Cash Equivalents | 2.31B |
| Total Debt | 22.94B |
| Net Cash | -20.63B |
| Net Cash Per Share | -44.28 |
| Equity (Book Value) | 83.40B |
| Book Value Per Share | 178.47 |
| Working Capital | 6.61B |
Cash Flow
In the last 12 months, operating cash flow was 9.86 billion and capital expenditures -3.51 billion, giving a free cash flow of 6.35 billion.
| Operating Cash Flow | 9.86B |
| Capital Expenditures | -3.51B |
| Depreciation & Amortization | 4.55B |
| Net Borrowing | -2.19B |
| Free Cash Flow | 6.35B |
| FCF Per Share | 13.62 |
Margins
Gross margin is 56.39%, with operating and profit margins of 23.30% and 14.70%.
| Gross Margin | 56.39% |
| Operating Margin | 23.30% |
| Pretax Margin | 18.68% |
| Profit Margin | 14.70% |
| EBITDA Margin | 37.46% |
| EBIT Margin | 23.30% |
| FCF Margin | 19.76% |
Dividends & Yields
This stock pays an annual dividend of 6.50, which amounts to a dividend yield of 1.50%.
| Dividend Per Share | 6.50 |
| Dividend Yield | 1.50% |
| Dividend Growth (YoY) | 2.33% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 64.19% |
| FCF Payout Ratio | 48.45% |
| Buyback Yield | -64.53% |
| Shareholder Yield | -63.03% |
| Earnings Yield | 2.37% |
| FCF Yield | 3.18% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Novozymes is 499.33, which is 15.13% higher than the current price. The consensus rating is "Buy".
| Price Target | 499.33 |
| Price Target Difference | 15.13% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 7.44% |
| EPS Growth Forecast (3Y) | 9.97% |
Stock Splits
The last stock split was on November 28, 2011. It was a forward split with a ratio of 5.
| Last Split Date | Nov 28, 2011 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Novozymes has an Altman Z-Score of 4.19 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.19 |
| Piotroski F-Score | 6 |